Hepatitis C

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Dec 10, 2014
popularity not rated yet | comments 0

Health care M&A leads global deal surge

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

Nov 23, 2014
popularity 5 / 5 (1) | comments 0

HIV risks high in Mexico City's male sex trade

A new study documents the stark health dangers of the male sex trade in the streets, hotels, and discotheques of Mexico City. Lead author and health economist Omar Galárraga's point in making the grim assessment ...

Nov 14, 2014
popularity 5 / 5 (1) | comments 0

Latest Spotlight News

Protein may be key to cancer's deadly resurgences

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

Study shows who benefits most from statins

New research suggests that widely used statin therapy provides the most benefit to patients with the highest genetic risk of heart attack. Using a relatively straightforward genetic analysis, the researchers ...